Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 5/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502548 | 0.85 | SRC (0.47) | SRCFGFR1BRPF1ABL1ANPEP | |
| SCHEMBL502110 | 0.83 | SRC (0.51) | SRCFGFR1BRPF1ABL1MEN1 | |
| SCHEMBL12400045 | 0.81 | SRC (0.36) | SRCFGFR1LYNBTKABL1 | |
| SCHEMBL855319 | 0.80 | SYK (0.39) | SRCFGFR1LYNBTKALDH1A1 | |
| SCHEMBL855318 | 0.80 | SYK (0.39) | SRCFGFR1LYNBTKALDH1A1 | |
| SCHEMBL10043818 | 0.77 | SYK (0.54) | SRCFGFR1MEN1NPC1ALDH1A1 | |
| SCHEMBL880924 | 0.76 | BRPF1 (0.49) | SRCFGFR1BRPF1ANPEPDPP4 | |
| SCHEMBL10043820 | 0.75 | GRM1 (0.44) | SRCFGFR1FGFR4 | |
| SCHEMBL10043819 | 0.75 | SYK (0.43) | SRCFGFR1MEN1NPC1ALDH1A1 | |
| SCHEMBL854149 | 0.74 | SYK (0.36) | SRCFGFR1LYNBTKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| EP-2252612-B1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2012-03-28 | — | — | EP | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| EP-2252612-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009105712-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105712-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | SRC 302/4885FGFR1 208/4885BRPF1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.